| Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients L Balogh, É Katona, ZA Mezei, J Kállai, R Gindele, I Édes, L Muszbek, ... Molecular and Cellular Biochemistry 448, 199-209, 2018 | 18 | 2018 |
| Deficiencies of the natural anticoagulants–novel clinical laboratory aspects of thrombophilia testing Z Bereczky, R Gindele, M Speker, J Kállai Ejifcc 27 (2), 130, 2016 | 17 | 2016 |
| Factor XIII levels and factor XIII B subunit polymorphisms in patients with venous thromboembolism ZA Mezei, É Katona, J Kállai, Z Bereczky, L Somodi, É Molnár, B Kovács, ... Thrombosis research 158, 93-97, 2017 | 14 | 2017 |
| Regulation of plasma factor XIII levels in healthy individuals; a major impact by subunit B intron K c. 1952+ 144 C> G polymorphism ZA Mezei, É Katona, J Kállai, Z Bereczky, É Molnár, B Kovács, É Ajzner, ... Thrombosis research 148, 101-106, 2016 | 12 | 2016 |
| Investigation of the differences in antithrombin to heparin binding among antithrombin Budapest 3, Basel, and Padua mutations by biochemical and in silico methods R Gindele, K Pénzes-Daku, G Balogh, J Kállai, R Bogáti, B Bécsi, ... Biomolecules 11 (4), 544, 2021 | 10 | 2021 |
| A novel mutation in SLC39A7 identified in a patient with autosomal recessive agammaglobulinemia: The impact of the J Project M Erdős, K Mironska, L Kareva, K Stavric, A Hasani, Á Lányi, J Kállai, ... Pediatric Allergy and Immunology 33 (6), 2022 | 6 | 2022 |
| Resolving differential diagnostic problems in von willebrand disease, in fibrinogen disorders, in prekallikrein deficiency and in hereditary hemorrhagic telangiectasia by next … R Gindele, A Kerényi, J Kállai, G Pfliegler, Á Schlammadinger, I Szegedi, ... Life 11 (3), 202, 2021 | 6 | 2021 |
| Novel STAT-3 gain-of-function variant with hypogammaglobulinemia and recurrent infection phenotype M Erdős, M Tsumura, J Kállai, Á Lányi, Z Nyul, G Balázs, S Okada, ... Clinical & Experimental Immunology 205 (3), 354-362, 2021 | 5 | 2021 |
| The Voltage-Gated Hv1 H+ Channel Is Expressed in Tumor-Infiltrating Myeloid-Derived Suppressor Cells M Cozzolino, A Gyöngyösi, E Korpos, P Gogolak, MU Naseem, J Kállai, ... International Journal of Molecular Sciences 24 (7), 6216, 2023 | 4 | 2023 |
| Effect of α2-plasmin inhibitor heterogeneity on the risk of venous thromboembolism B Baráth, R Bogáti, T Miklós, J Kállai, ZA Mezei, Z Bereczky, L Muszbek, ... Thrombosis Research 203, 110-116, 2021 | 2 | 2021 |
| Potential Role of VHL, PTEN, and BAP1 Mutations in Renal Tumors K Szegedi, Z Szabó, J Kállai, J Király, E Szabó, Z Bereczky, É Juhász, ... Journal of Clinical Medicine 12 (13), 4538, 2023 | 1 | 2023 |
| Clinical and Molecular Characterization of Nine Novel Antithrombin Mutations J Kállai, R Gindele, K Pénzes-Daku, G Balogh, R Bogáti, B Bécsi, ... International Journal of Molecular Sciences 25 (5), 2893, 2024 | | 2024 |
| 5-Chloro-2-Guanidinobenzimidazole (ClGBI) Is a Non-Selective Inhibitor of the Human HV1 Channel TG Szanto, A Feher, E Korpos, A Gyöngyösi, J Kállai, B Mészáros, K Ovari, ... Pharmaceuticals 16 (5), 656, 2023 | | 2023 |
| Identification of a new family of inhibitors of the human Hv1 proton channel A Feher, E Korpos-Pintye-Gyuri, M Piga, T Tomasic, N Zidar, A Gyongyosi, ... Biophysical Journal 122 (3), 256a-257a, 2023 | | 2023 |
| A novel mutation in SLC39A7 identified in a patient with autosomal recessive agammaglobulinemia M Erdős, K Mironska, L Kareva, K Stavrik, A Hasani, A Lanyi, J Kallai, ... Authorea Preprints, 2022 | | 2022 |
| Feno-and genotyping von Willebrand disease type 2A patient because of spontaneous tonsilliar haemorrhage J Harsfalvi, ML Udvardy, J Kallai, A Kerenyi, I Szegedi, E Marjan, C Kiss JOURNAL OF THROMBOSIS AND HAEMOSTASIS 11, 1181-1181, 2013 | | 2013 |
| Rizs protein foszfatáz 2A B''alegység expressziójára alkalmas vektorkonstrukciók készítése J Kállai | | |
| A novel mutation in identified in a patient with autosomal recessive agammaglobulinemia: the impact of the J-Project M Erdős, K Mironska, L Kareva, K Stavrik, A Hasani, Á Lányi, J Kállai, ... | | |
